Molnupiravir in COVID-19: A systematic review of literature
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
Molnupiravir and its antiviral activity against COVID-19
L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] RdRp inhibitors and COVID-19: Is molnupiravir a good option?
SMR Hashemian, MH Pourhanifeh, MR Hamblin… - Biomedicine & …, 2022 - Elsevier
Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …
Molnupiravir: first approval
YY Syed - Drugs, 2022 - Springer
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
Molnupiravir—a novel oral anti-SARS-CoV-2 agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
S Masyeni, M Iqhrammullah… - Journal of Medical …, 2022 - Wiley Online Library
Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …